Vanguard Group Inc Galectin Therapeutics Inc Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,116,072 shares of GALT stock, worth $5.73 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,116,072
Previous 1,979,891
6.88%
Holding current value
$5.73 Million
Previous $4.73 Million
1.08%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding GALT
# of Institutions
75Shares Held
9.35MCall Options Held
982KPut Options Held
2.7K-
Black Rock Inc. New York, NY1.56MShares$4.24 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.13MShares$3.05 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA842KShares$2.28 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.31 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$1.08 Million0.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $161M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...